On Sept. 6, 2017, PATH announced it has received a $120 million grant from the Bill & Melinda Gates Foundation to further strengthen its PATH Center for Vaccine Innovation and Access (CVIA), which works across every stage of vaccine research, development, and introduction for diseases in low-resource settings.

PATH also announced that several global experts in vaccine development and introduction have joined PATH CVIA to advance these critical vaccine efforts.

CVIA operates across the entire vaccine development and delivery spectrum—from preclinical research on novel candidates through pivotal clinical evaluations and, ultimately, innovative approaches for new vaccine introduction.

PATH is known for its deep engagement with multiple partners, including national immunization program managers and ministries of health to provide crucial insights; scientists and clinical researchers to develop and evaluate novel approaches to vaccines in real-world conditions; manufacturers to accelerate development; global agencies like the World Health Organization and UNICEF; financing bodies like Gavi, the Vaccine Alliance; and governments to support immunization implementation.

PATH works with communities to understand their needs and priorities, and gain commitment to pricing and distribution strategies that ensure accessibility, availability, affordability, acceptability, and sustainability.